BACKGROUND: We have previously reported that macrophage migration-inhibitory factor (MIF) is associated with an unfavorable prognosis in hypopharyngeal carcinoma. Here, we quantified MIF expression in oral cavity carcinomas and looked for possible correlations with clinical outcome. MATERIALS AND METHODS: MIF expression was assessed by immunohistochemistry in a cohort of 154 oral cavity carcinomas and was compared to eight specimens of tumor-free epithelia, 32 cases of low-grade dysplasia and 137 cases of high-grade dysplasia. RESULTS: Marked increases in MIF-immunostaining intensity and MIF-positive tissue areas were seen in carcinomas as compared to dysplasia (p<10(-6)). MIF expression showed no correlation with recurrence, but was significantly higher (p=0.01) when a second primary tumor occurred. In addition, HPV(+) malignancies exhibited lower MIF expression. CONCLUSION: Our study revealed an association between tissue MIF levels and tumor progression in oral cavity carcinomas. Of note, high-level MIF expression was found in patients developing a second tumor during the follow-up period.
BACKGROUND: We have previously reported that macrophage migration-inhibitory factor (MIF) is associated with an unfavorable prognosis in hypopharyngeal carcinoma. Here, we quantified MIF expression in oral cavity carcinomas and looked for possible correlations with clinical outcome. MATERIALS AND METHODS:MIF expression was assessed by immunohistochemistry in a cohort of 154 oral cavity carcinomas and was compared to eight specimens of tumor-free epithelia, 32 cases of low-grade dysplasia and 137 cases of high-grade dysplasia. RESULTS: Marked increases in MIF-immunostaining intensity and MIF-positive tissue areas were seen in carcinomas as compared to dysplasia (p<10(-6)). MIF expression showed no correlation with recurrence, but was significantly higher (p=0.01) when a second primary tumor occurred. In addition, HPV(+) malignancies exhibited lower MIF expression. CONCLUSION: Our study revealed an association between tissue MIF levels and tumor progression in oral cavity carcinomas. Of note, high-level MIF expression was found in patients developing a second tumor during the follow-up period.
Authors: Steve Oghumu; Thomas J Knobloch; Cesar Terrazas; Sanjay Varikuti; Jennifer Ahn-Jarvis; Claire E Bollinger; Hans Iwenofu; Christopher M Weghorst; Abhay R Satoskar Journal: Int J Cancer Date: 2016-06-16 Impact factor: 7.396
Authors: Nadège Kindt; Jérôme R Lechien; Denis Nonclercq; Guy Laurent; Sven Saussez Journal: J Cancer Res Clin Oncol Date: 2014-03-25 Impact factor: 4.553
Authors: Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham Journal: PLoS One Date: 2017-09-28 Impact factor: 3.240
Authors: Kyriaki Ioannou; Kai Fan Cheng; Gregg V Crichlow; Anastasios I Birmpilis; Elias J Lolis; Ourania E Tsitsilonis; Yousef Al-Abed Journal: Int J Oncol Date: 2014-07-22 Impact factor: 5.650
Authors: Gary A Clawson; Gail L Matters; Ping Xin; Yuka Imamura-Kawasawa; Zhen Du; Diane M Thiboutot; Klaus F Helm; Rogerio I Neves; Thomas Abraham Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240
Authors: Mariana Barbosa DE Souza; Otávio Alberto Curioni; Jossi Ledo Kanda; Marcos Brasilino DE Carvalho Journal: Oncol Lett Date: 2014-09-09 Impact factor: 2.967